Nektar Therapeutics | NKTR - Stock


Nektar Therapeutics reported $14.46M in Stock for its fiscal quarter ending in June of 2024.





Stock Change Date
Agios Pharmaceuticals USD 35.09M 2.17M Mar/2026
ALKERMES USD 336.7M 140.08M Mar/2026
Amgen USD 6.19B 39M Mar/2026
Baxter International USD 2.32B 84M Mar/2026
BioCryst Pharmaceuticals USD 5.98M 587K Mar/2026
Biogen USD 1.95B 219.1M Mar/2026
Bristol-Myers Squibb USD 2.76B 66M Mar/2026
Cara Therapeutics USD 900K 0 Mar/2025
Cipla INR 61.6B 5.18B Sep/2025
Dr.Reddys Laboratories INR 79.01B 3.19B Dec/2025
Eisai JPY 236.46B 9.14B Sep/2025
Eli Lilly USD 14.53B 785M Mar/2026
Esperion Therapeutics USD 104.21M 915K Mar/2026
Exelixis USD 26.6M 4.92M Mar/2026
Gilead Sciences USD 1.91B 140M Mar/2026
GlaxoSmithKline GBP 6.16B 233M Mar/2026
Grifols EUR 3.56B 63.19M Dec/2024
Halozyme Therapeutics USD 155.47M 21.01M Mar/2026
Incyte USD 115.62M 14.56M Mar/2026
Ionis Pharmaceuticals USD 5.56M 4.49M Mar/2026
Karyopharm Therapeutics USD 4.04M 72K Dec/2025
MacroGenics USD 9.5M 1.59M Mar/2026
Merck USD 6.48B 179M Mar/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 64.5M 4.5M Mar/2026
Novartis USD 6.29B 17M Mar/2026
Pfizer USD 10.67B 13M Mar/2026
Roche Holding CHF 7.6B 9M Jun/2025
Sarepta Therapeutics USD 1B 86.37M Mar/2026
Takeda JPY 1.41T 107.71B Dec/2025
Teva Pharmaceutical Industries USD 3.18B 144M Dec/2025